CVE-2026-127393: Oracle Product Lifecycle Analytics · Easily exploitable vulnerability allows low privileged attacker with logon to the infrastructure
Affects Oracle Product Lifecycle AnalyticsSource CVE Database V5
Not known to be exploited · CVSS 6.5 Medium.
Data as of 17 Nov 2026, 22:34 UTC
Thin evidence
One scorer or none| CNA (oracle) | CVSS 3.1 | 6.5 |
|---|
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:C/C:H/I:N/A:NExploitation evidence
Disclosed: evidence found.
CVE published 17 Nov 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponized: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors
A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 17 Nov 2026.
What to do
Affected software
| Product | Affected | Fixed in |
|---|---|---|
| Oracle CorporationProduct Lifecycle Analytics | Affected
| Fixed in– |
AI-suggested
Oracle strongly recommends that customers remain on actively-supported versions and apply all relevant security patches without delay. Although the advisory does not specify a direct patch for Product Lifecycle Analytics 3.6.1, the Critical Security Patch Update released in November 2026 addresses numerous vulnerabilities across Oracle products. Customers should consult the Oracle Critical Security Patch Update documentation and apply the appropriate patches for their environment promptly to mitigate this vulnerability.
Description
CVE-2026-127393 is a vulnerability in Oracle's Product Lifecycle Analytics version 3.6.1 that allows a low privileged attacker with logon access to the infrastructure to compromise the product. The vulnerability can lead to unauthorized access to critical data within Product Lifecycle Analytics and may affect additional products due to scope change. The CVSS 3.1 base score is 6.5, indicating a medium severity with significant confidentiality impact but no integrity or availability impact.